Close Menu

Guardant Health

The assay uses RT-PCR and next-generation sequencing to detect coronavirus SARS-CoV-2 nucleic acids from upper respiratory nasal specimens.

Streck said its collection tube maintains native cell-free DNA populations and provides sample integrity by reducing the release of cellular genomic DNA.

The company was able to ramp up recruitment for its pivotal ECLIPSE trial after hurdles caused a falloff during the earlier months of the COVID-19 pandemic.

The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.

Although its research test volume decreased significantly because of the COVID-19 pandemic, the company saw revenue growth across both clinical testing and development services.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab. 

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

News items for the in vitro diagnostics industry for the week of June 8, 2020.

Pages